Commvault Systems Inc vs Heron Therapeutics Inc — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: Commvault Systems Inc is far larger — about 91.9× Heron Therapeutics Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Heron Therapeutics Inc for 35 Days on average.
| CVLT | HRTX | |
|---|---|---|
Market Cap | $6.25B | $68.01M |
Volume | 632,727 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $176.52 | $1.49 |
52-Week Low | $75.18 | $0.27 |
Typical Hold Time | 17 Days | 35 Days |
Enterprise Value | $6.24B | $174.75M |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 81.09% gross margins and 32.77% ROE. Recent business developments include achieving AWS Data Competency and expanding FedRAMP High authorized services, positioning the company for continued growth in the cybersecurity resilience market.
CVLT presents a compelling growth story with strong fundamentals and positive analyst sentiment, though elevated valuation ratios (P/E 96.73, P/B 120.15) suggest premium pricing. The primary investment opportunity lies in the company's leadership in AI-era resilience solutions, while risks include valuation sensitivity and competitive pressures in the enterprise software space. Wall Street maintains a bullish stance with 54.55% buy ratings and a $156.55 consensus price target.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →